# Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

> **NCT03573882** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 179 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Voxelotor

## Key facts

- **NCT ID:** NCT03573882
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-06
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 179 (ACTUAL)
- **Why stopped:** Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573882, "Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03573882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*